VolitionRX Limited (AMEX:VNRX) life sciences firm, is expected to report second quarter earnings results, after market close, on Thursday 13th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.12 per share from revenue of $ 0.02 million.
Looking ahead, the full year loss are expected at $ 0.48 per share on the revenues of $ 0.24 million.
Previous Quarter Performance
VolitionRX Limited unveiled loss for the first quarter of $ 0.14 per share, from the revenue of $ 0.54 million. According to street consensus, loss of $ 0.10 was expected per share The bottom line results missed street analysts by $ 0.04 or 40 percent, at the same time, top line results analysts by $ 4.32 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of VNRX was $ 3.37, representing a 51.80 % increase from the 52 week low of $ 2.22 and a 50.73 % decrease over the 52 week high of $ 6.84.
The company has a market capital of $ 155.78 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”VNRX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
